Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://arstechnica.com/science/2023/01/ftc-shkreli-may-have-violated-lifetime-pharma-ban-should-be-held-in-contempt/
0
0
FTC: Shkreli may have violated lifetime pharma ban, should be held in contempt - Ars Technica
1/20/23 at 10:21pm
Organization
Ars Technica
Author
Beth Mole
Details
28 words
Summarize
Business & Industrial
Ars Technica Shkreli
FTC
lifetime pharma ban
Druglike
Shkreli's latest company, Druglike, may run afoul of his lifetime pharma ban.
Show more
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...